SAN DIEGO — A novel, oral therapeutic for treatment of migraine was safe and well-tolerated in single ascending doses in a cohort of healthy adults, according to a speaker at the American Headache Society Annual Scientific Meeting.
“There’s strong mechanistic evidence of the role of triptan-3 in neurogenic inflammation,” Richard Bertz, PhD, senior VP of clinical pharmacology at Biohaven Pharmaceuticals, told attendees. “There’s also an expression profile in the human trigeminal vascular system that indicates a potential functional role in migraine